• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer.

作者信息

Zhao Hong, Li Rong, Wang Xiaoyan, Lu Xin, Hu Min, Zhang Jinbin, Zhao Xia, Song Xiaoqin, Liu Yangyang

机构信息

Department of Biochemistry and Molecular Biology, Basic Medical College, Shanxi Medical University, No. 56 Xinjian South Road, Yingze District, Taiyuan City, Shanxi Province, China.

Department of Gynecology, Shanxi Cancer Hospital, Taiyuan, China.

出版信息

J Ovarian Res. 2021 Feb 19;14(1):37. doi: 10.1186/s13048-021-00785-1.

DOI:10.1186/s13048-021-00785-1
PMID:33608028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7896362/
Abstract
摘要

相似文献

1
Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer.撤稿说明：阿帕替尼联合紫杉醇（白蛋白结合型）在铂耐药卵巢癌中的作用
J Ovarian Res. 2021 Feb 19;14(1):37. doi: 10.1186/s13048-021-00785-1.
2
Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study.阿帕替尼治疗铂耐药复发性上皮性卵巢癌的疗效与安全性：一项真实世界研究
Drug Des Devel Ther. 2019 Nov 15;13:3913-3918. doi: 10.2147/DDDT.S220847. eCollection 2019.
3
Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.阿帕替尼联合依托泊苷口服治疗铂耐药或铂抵抗复发性卵巢癌（AEROC）的Ⅱ期、单臂、前瞻性研究。
Lancet Oncol. 2018 Sep;19(9):1239-1246. doi: 10.1016/S1470-2045(18)30349-8. Epub 2018 Aug 3.
4
Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases.阿帕替尼联合拓扑替康用于铂耐药复发性卵巢癌患者的多线治疗：三例报告
Onco Targets Ther. 2018 Apr 6;11:1989-1995. doi: 10.2147/OTT.S158141. eCollection 2018.
5
Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study.阿帕替尼联合依托泊苷治疗铂耐药复发性上皮性卵巢癌患者的疗效和安全性：一项回顾性研究
J Cancer. 2020 Jul 9;11(18):5353-5358. doi: 10.7150/jca.45547. eCollection 2020.
6
Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.低剂量阿帕替尼治疗铂耐药或铂抵抗复发性卵巢癌患者的疗效和安全性：一项单中心回顾性研究。
Cancer Med. 2020 Aug;9(16):5899-5907. doi: 10.1002/cam4.3282. Epub 2020 Jul 6.
7
Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.阿帕替尼维持治疗铂耐药复发性卵巢癌的疗效及文献复习。
Cancer Biol Ther. 2018;19(12):1088-1092. doi: 10.1080/15384047.2018.1491500. Epub 2018 Aug 15.
8
Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial.脂肪组织面积作为评估阿帕替尼治疗铂耐药卵巢癌疗效的预测因子：AEROC 试验的探索性影像学生物标志物分析。
BMC Med. 2020 Oct 5;18(1):267. doi: 10.1186/s12916-020-01733-4.
9
A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.阿帕替尼治疗复发性上皮性卵巢癌的 II 期研究。
Gynecol Oncol. 2018 Feb;148(2):286-290. doi: 10.1016/j.ygyno.2017.12.013. Epub 2017 Dec 18.
10
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.帕唑帕尼联合每周紫杉醇与单独每周紫杉醇治疗铂耐药或铂难治性晚期卵巢癌（MITO 11）：一项随机、开放标签、2 期试验。
Lancet Oncol. 2015 May;16(5):561-8. doi: 10.1016/S1470-2045(15)70115-4. Epub 2015 Apr 14.

引用本文的文献

1
Mechanism of microRNA-152-3p-Mediated Regulation of Autophagy and Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells.微小RNA-152-3p介导的紫杉醇耐药卵巢癌细胞自噬及敏感性调控机制
Onco Targets Ther. 2025 Feb 4;18:179-197. doi: 10.2147/OTT.S485100. eCollection 2025.

本文引用的文献

1
The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer.阿帕替尼联合紫杉醇（铝结合型）在铂耐药卵巢癌中的作用。
J Ovarian Res. 2020 Sep 21;13(1):113. doi: 10.1186/s13048-020-00719-3.